Description
What Is Orforglipron and How Does It Work?
Orforglipron belongs to the same drug class as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) — GLP-1 receptor agonists. It mimics glucagon-like peptide-1 (GLP-1), a hormone your gut naturally releases after eating, acting on receptors in the gut and brain to help regulate appetite, fullness, and blood sugar.
What sets it apart is chemistry, not just format: unlike peptide-based GLP-1 drugs, which break down in stomach acid and therefore need to be injected (or, in the case of oral semaglutide, taken on a strict empty-stomach routine), orforglipron is a small, non-peptide molecule. That makes it stable enough to be taken as a tablet, at any time of day, with or without food or water.
In clinical trials, people commonly reported:
- Reduced hunger and fewer food cravings
- Feeling fuller sooner, and staying full for longer
- Easier portion control at meals
- More stable energy levels between meals
Clinical Trial Results
In Eli Lilly's Phase 3 ATTAIN programme, participants on the highest dose lost an average of around 11–12% of their body weight over 72 weeks, compared with roughly 2% on placebo. Just over half of participants on the highest dose lost at least 10% of their starting body weight.
As with all GLP-1 medicines, results vary significantly by individual, dose, and adherence to a structured diet and exercise plan — orforglipron is not a standalone treatment.
Safety Considerations
Like other GLP-1 medicines, Foundayo carries a boxed warning in the US relating to thyroid C-cell tumours observed in animal studies (this risk hasn't been confirmed in humans). It isn't recommended for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects reported in trials were largely gastrointestinal (nausea, diarrhoea, constipation), consistent with the wider GLP-1 class.
Who Might Orforglipron Be Suitable For?
Final UK eligibility criteria will be set once the MHRA issues a licence, but based on the US label and typical UK GLP-1 prescribing patterns, it's expected to be considered for:
- Adults with a BMI of 30+ (obesity)
- Adults with a BMI of 27+ who also have a weight-related condition (e.g. type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea)
- People who'd prefer a daily tablet over a weekly injection
- People who struggle with the strict fasted-morning routine required by Rybelsus (oral semaglutide)
As with Wegovy and Mounjaro, it's intended to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.
Side Effects
Possible Side Effects
As with other GLP-1 medicines, the most commonly reported side effects in orforglipron's clinical trials were gastrointestinal, and tended to be more common at higher doses:
- Nausea
- Diarrhoea
- Constipation
- Vomiting
- Indigestion
- Reduced appetite
These effects were usually mild to moderate and often eased over time. In trials, between roughly 5% and 10% of participants stopped treatment because of side effects, compared with under 3% on placebo.
Boxed warning: In the US, Foundayo carries a boxed warning about thyroid C-cell tumours, based on findings in animal studies. This risk hasn't been confirmed in humans, but the medicine isn't recommended for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Not suitable for everyone. As with all GLP-1 medicines, suitability depends on individual medical history — including pregnancy, other medications, and existing conditions. This is general information, not medical advice, and final UK prescribing guidance will be confirmed once the MHRA reviews the medicine.
Directions
Orforglipron is taken as one tablet, once daily, at any time of day, with or without food or water.
To reduce gastrointestinal side effects, the dose is increased gradually over several months:
- Maximum dose: 17.2 mg once daily
- Dose increases happen no more often than every 30 days, and only if the current dose is well tolerated
- If side effects are troublesome at a given step, it's common practice to stay on that dose a little longer before increasing
- Tablets should be swallowed whole
- Missed dose: take it as soon as remembered on the same day; don't double up the next day
- Should not be combined with another GLP-1 receptor agonist medicine
FAQs
Is orforglipron the same as Foundayo?
Yes. Orforglipron is the drug's chemical/generic name; Foundayo is Eli Lilly's brand name for it in the US.
Can I buy orforglipron in the UK right now?
No. It has no UK marketing authorisation, so no licensed UK pharmacy can legally supply it yet.
When will orforglipron be available in the UK?
There's no confirmed date. Based on typical MHRA review timelines following the April 2026 US approval, private UK availability is realistically expected sometime between late 2026 and 2027, with NHS access via NICE likely to follow later.
Is orforglipron the same as the Wegovy pill?
No. Both are oral GLP-1 tablets, but the Wegovy pill is oral semaglutide (a peptide, requiring a fasted morning routine), while orforglipron is a different, non-peptide small molecule that can be taken with or without food.
What can I take instead of orforglipron in the UK today?
Wegovy and Mounjaro are both MHRA-approved and available now through regulated UK pharmacies, including 24hrpharmacy.co.uk.
What They Say About Us...
Great service, the follow up phone call to ensure that I was getting the correct medication was appreciated. Would yes 24 HR Pharmacy again.
Excellent customer service and prompt communication. My enquiry was resolved quickly, and my order was delivered ahead of time.
The service I received was faultless. Sehar is very knowledgeable and supportive in her consultation. The service was quick and easy to use.
The service I received was faultless. Sehar is very knowledgeable and supportive in her consultation. The service was quick and easy to use.